CA2217020A1 - Heregulines de recombinaison et leurs fonctions biologiques lors de l'activation d'un recepteur - Google Patents

Heregulines de recombinaison et leurs fonctions biologiques lors de l'activation d'un recepteur Download PDF

Info

Publication number
CA2217020A1
CA2217020A1 CA002217020A CA2217020A CA2217020A1 CA 2217020 A1 CA2217020 A1 CA 2217020A1 CA 002217020 A CA002217020 A CA 002217020A CA 2217020 A CA2217020 A CA 2217020A CA 2217020 A1 CA2217020 A1 CA 2217020A1
Authority
CA
Canada
Prior art keywords
beta
growth factor
fusion protein
rhrg
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002217020A
Other languages
English (en)
Inventor
Jean-Michel Culouscou
Gary W. Carlton
Alejandro A. Aruffo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2217020A1 publication Critical patent/CA2217020A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Veterinary Medicine (AREA)

Abstract

L'invention porte sur la production d'hérégulines de recombinaison polyvalentes ainsi que sur quelques fonctions biologiques et voies de signalisation intracellulaires déclenchées par ces protéines à la suite de l'activation d'un récepteur. L'invention a également trait au clonage de fragments d'ADN complémentaire codant le domaine du type EGF de l'héréguline-.alpha., .beta.2 ou .beta.3 dans un vecteur d'expression eucaryote et à la transfection de ce vecteur dans des cellules mammaliennes. Ces hérégulines de recombinaison s'avèrent utiles dans le cadre de l'activation du récepteur HER4.
CA002217020A 1995-05-16 1996-05-14 Heregulines de recombinaison et leurs fonctions biologiques lors de l'activation d'un recepteur Abandoned CA2217020A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44186395A 1995-05-16 1995-05-16
US08/441,863 1995-05-16

Publications (1)

Publication Number Publication Date
CA2217020A1 true CA2217020A1 (fr) 1996-11-21

Family

ID=23754597

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002217020A Abandoned CA2217020A1 (fr) 1995-05-16 1996-05-14 Heregulines de recombinaison et leurs fonctions biologiques lors de l'activation d'un recepteur

Country Status (5)

Country Link
EP (1) EP0828843A1 (fr)
JP (1) JPH11505124A (fr)
CA (1) CA2217020A1 (fr)
MX (1) MX9708529A (fr)
WO (1) WO1996036720A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5713848A (en) 1993-05-19 1998-02-03 Dubrul; Will R. Vibrating catheter
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
EP0970207B1 (fr) * 1997-02-10 2009-04-01 Genentech, Inc. Variants d'hereguline
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
ZA986077B (en) 1997-07-09 2000-01-10 Genentech Inc ErbB4 receptor-specific neuregulin related ligands and uses therefor.
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
US6994856B1 (en) 1997-07-24 2006-02-07 Genentech, Inc. ErbB4 receptor-specific neuregulin related ligands and uses therefor
IL137419A0 (en) * 2000-07-20 2001-07-24 Yissum Res Dev Co Nk cells activating receptors and their therapeutic and diagnostic uses
CN102676571A (zh) * 2011-11-18 2012-09-19 北京市结核病胸部肿瘤研究所 一种真核蛋白表达载体及其构建和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01211490A (ja) * 1988-02-19 1989-08-24 Tosoh Corp ヒト神経成長因子遺伝子セグメント

Also Published As

Publication number Publication date
JPH11505124A (ja) 1999-05-18
MX9708529A (es) 1998-02-28
EP0828843A1 (fr) 1998-03-18
WO1996036720A1 (fr) 1996-11-21

Similar Documents

Publication Publication Date Title
Kashishian et al. Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo.
Livneh et al. Release of a phorbol ester-induced mitogenic block by mutation at Thr-654 of the epidermal growth factor receptor
JP3561268B2 (ja) レセプターチロシンキナーゼ標的タンパク質のｃＤＮＡクローニング方法及びｈＧＲＢタンパク質
Jiang et al. Receptor-like protein tyrosine phosphatase α homodimerizes on the cell surface
US5916755A (en) Methods of characterizing ligands for the erbB-3 receptor, methods of influencing erbB-3 activities and methods of diagnosing erbB-3-related neoplasm
JP3039802B2 (ja) 繊維芽細胞成長因子のための受容体
US7718384B2 (en) Soluble ErbB3 method of detection
Burke et al. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation
DK2248899T3 (en) Nogo receptor-binding protein
US7744882B2 (en) Soluble ErbB3 methods of detection and antibodies
Yokote et al. Identification of Tyr-762 in the platelet-derived growth factor α-receptor as the binding site for Crk proteins
CA2217020A1 (fr) Heregulines de recombinaison et leurs fonctions biologiques lors de l'activation d'un recepteur
WO2003011908A2 (fr) FORMES MUTANTES DU RECEPTEUR TGF-β DE TYPE II LIANT TOUS LES ISOFORMES TGF-β
US7390632B2 (en) Soluble ErbB3 receptor isoforms
MXPA97008529A (en) Recombinant herregulins and their biological functions on recep activation
Culouscou et al. HER4 Receptor Activation and Phosphorylation of Shc Proteins by Recombinant Heregulin-Fc Fusion Proteins (∗)
Abrescia et al. Drosophila RET contains an active tyrosine kinase and elicits neurotrophic activities in mammalian cells
Dye et al. hShroom1 links a membrane bound protein to the actin cytoskeleton
WO2009157919A1 (fr) Détection de erbb3 soluble, régulation et traitement du cancer
US5677421A (en) Target proteins for eukaryotic tyrosine kinases
US7745398B2 (en) Soluble ErbB3 and treatment of cancer
QIAN et al. Identification of pl85neu sequences required for monoclonal antibody-or ligand-mediated receptor signal attenuation
US5807989A (en) Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
Yang et al. Demonstration of the interaction of transforming growth factor beta 2 and type X collagen using a modified tandem affinity purification tag
WO2000027865A1 (fr) CARACTERISATION D'UN GENE cbl-SL NOUVEAU

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20040514